A new approach for the detection of type III hyperlipoproteinemia by RLP-cholesterol assay.
Type III is a remnant hyperlipoproteinemia identified by the presence of beta-VLDL (remnant lipoprotein) as well as a genetic variant of apo E (apo E2/2). The RLP isolated from the serum of Type III patients by a new method we have developed, the RLPcholesterol assay, was identified as chylomicron and VLDL remnant. In addition, the RLP-C levels of the Type III patients were significantly higher than other hyperlipidemic patients with similar serum TG levels, while the ratio of TC/TG in RLP-C of both groups was not significantly different. The RLP-cholesterol assay appears to be useful for the screening and monitoring of Type III hyperlipoproteinemia when used in conjunction with the assays of serum TG level and genetic apo E isoform analysis.
Nakajima
K
K
Japan Immunoresearch Laboratories, Takasaki, Gunma, Japan.
Saito
T
T
Tamura
A
A
Suzuki
M
M
Nakano
T
T
Adachi
M
M
Tanaka
A
A
Tada
N
N
Nakamura
H
H
Murase
T
T
D000328:Adult; D000368:Aged; D015243:Cholesterol, VLDL / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood*; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D014280:Triglycerides / Q000097:blood
D015243:Cholesterol, VLDL; D014280:Triglycerides